Fate Therapeutics Details Off-the-Shelf CAR T Progress in Lupus and Solid Tumors at Needham Conference [Yahoo! Finance]
Fate Therapeutics, Inc. (FATE)
Last fate therapeutics, inc. earnings: 3/2 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.fatetherapeutics.com/investor-relations
Company Research
Source: Yahoo! Finance
B-cell depletion and clinical signal in SLE and other autoimmune conditions, can be dosed outpatient with same-day discharge, and has received RMAT designation with a planned potentially registration-enabling Phase II in lupus nephritis. iPSC manufacturing & cash runway — Fate leverages a single iPSC master cell bank (company cites the potential for 10 million doses) and a 40,000 sq ft facility capable of producing thousands of doses (scalable to ~50,000/year), and reported $200 million in cash with runway through 2027. Oncology progress — Next-generation candidates showed early proof-of-concept: FT836 (nine edits targeting MICA/MICB plus CD16) was detected in blood and tumor biopsies without conditioning and produced biomarker and tumor reductions in a colorectal patient, while FT839 is IND-enabling as a multi-target, heavily edited program for combination approaches. Interested in Fate Therapeutics, Inc.? Here are five stocks we like better. Fate Therapeutics (NASDAQ:FATE) u
Show less
Read more
Impact Snapshot
Event Time:
FATE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FATE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FATE alerts
High impacting Fate Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FATE
News
- Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR AnnuGlobeNewswire
- Fate Therapeutics to Participate in Upcoming Second Quarter 2026 ConferencesGlobeNewswire
- Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Scalable Biotech Manufacturing Unlocks a $14B MarketPR Newswire
- The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t NoticedGlobeNewswire
FATE
Earnings
- 11/13/25 - Beat
FATE
Sec Filings
- 3/26/26 - Form SCHEDULE
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- FATE's page on the SEC website